.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The PRORATA trial evaluated a procalcitonin-guided strategy for starting and stopping antibiotics in critically ill adults with suspected bacterial infection. The goal was to reduce unnecessary antimicrobial exposure without increasing mortality or recurrent infection. The trial showed that biomarker-guided treatment could reduce antibiotic exposure while maintaining comparable clinical outcomes. Procalcitonin was used within a predefined algorithm rather than interpreted in isolation. This is important for modern antimicrobial stewardship because prolonged antibiotic courses can drive toxicity and selection of multidrug-resistant organisms. At the same time, biomarkers are imperfect and should not be allowed to override obvious clinical evidence of ongoing infection or inadequate source control. CritiCARE 2026 explicitly discusses antibiotic stewardship, procalcitonin and antibiotic dosing in AKI, making this study highly relevant. For HCPs, the practical use of procalcitonin is as a structured aid to reassess whether continued antibiotics remain necessary. The strongest approach combines the trajectory of the patient, microbiology, source-control status, organ function and biomarker trends. The trial therefore supports a stewardship mindset: every antibiotic course should have a reassessment plan, an indication for continuation and a stopping decision.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The PRORATA trial evaluated a procalcitonin-guided strategy for starting and stopping antibiotics in critically ill adults with suspected bacterial infection. The goal was to reduce unnecessary antimicrobial exposure without increasing mortality or recurrent infection. The trial showed that biomarker-guided treatment could reduce antibiotic exposure while maintaining comparable clinical outcomes. Procalcitonin was used within a predefined algorithm rather than interpreted in isolation. This is important for modern antimicrobial stewardship because prolonged antibiotic courses can drive toxicity and selection of multidrug-resistant organisms. At the same time, biomarkers are imperfect and should not be allowed to override obvious clinical evidence of ongoing infection or inadequate source control. CritiCARE 2026 explicitly discusses antibiotic stewardship, procalcitonin and antibiotic dosing in AKI, making this study highly relevant. For HCPs, the practical use of procalcitonin is as a structured aid to reassess whether continued antibiotics remain necessary. The strongest approach combines the trajectory of the patient, microbiology, source-control status, organ function and biomarker trends. The trial therefore supports a stewardship mindset: every antibiotic course should have a reassessment plan, an indication for continuation and a stopping decision.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
